Drugs / urinary-derived human chorionic gonadotropin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04886726 | Dec 2021 → Nov 2028 expected | graft versus host disease | Henry Ford Health System | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | urinary-derived human chorionic gonadotropin | “urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis” NCT04886726 ↗ |
| Known as | uhCG | “urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis” NCT04886726 ↗ |
| Route | Subcutaneous | “uhCG/EGF subcutaneously” NCT04886726 ↗ |